|

Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer

RECRUITINGSponsored by National Taiwan University Hospital
Actively Recruiting
SponsorNational Taiwan University Hospital
Started2021-08-19
Est. completion2024-10-31
Eligibility
Age20 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04948437

Summary

Now, the investigators carried out a prospective study enrolling patients with thyroid cancer, who had received ablative thyroidectomy and /or radioactive iodine therapy for two more years. The investigators' study already enrolled seventy-three patients with thyroid cancer, and the investigators plan to enroll 30 new patients in this consecutive research study. All patients received total thyroidectomy under clinically surgical judgement in initial therapeutic option. The investigators also further found some difference between papillary thyroid cancer and follicular thyroid cancer, and the investigators will continue annually to closely monitor the change of U-Ex Tg and urinary exosomal galectin-3 between differently cellular types of thyroid cancers.

Eligibility

Age: 20 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* diagnosed patients with thyroid papillary, follicular and anaplastic thyroid cancer, post-operation follow up

Exclusion Criteria:

* unclearly diagnosed patients with thyroid papillary, follicular and anaplastic thyroid cancer

Conditions4

CancerFollicular Thyroid CancerPapillary Thyroid CancerThyroid Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.